AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35818232 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 regimen
Number of subjects: 60
Study 34373901 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motor cortex stimulation ('on')
Number of subjects: 18
Study 34373901 — intervention group
Group type: COMPARATOR
Intervention: Sham motor cortex stimulation ('off')
Number of subjects: 18
Study 34373901 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative analgesic effect after electrode insertion
Number of subjects: 18
Study 34373901 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Number of subjects: 18
Study 32374710 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training for oncologists (2-hour training and four coaching sessions)
Number of subjects: 265
Study 32374710 — intervention group
Group type: COMPARATOR
Intervention: Usual care for oncologists
Number of subjects: 265
Study 32374710 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training (INT)
Number of subjects: 265
Study 32374710 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 265
Study 32374710 — intervention group
Group type: EXPERIMENTAL
Intervention: INT group
Number of subjects: 265
Study 32374710 — intervention group
Group type: COMPARATOR
Intervention: UC group
Number of subjects: 265
Study 35276977 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SS (ONS up to 14 days preoperatively and postoperatively up to discharge)
Number of subjects: 91
Study 35276977 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SS-E (ONS up to 14 days preoperatively, postoperatively up to discharge and for an extended 90‐days after discharge)
Number of subjects: 91
Study 35276977 — intervention group
Group type: COMPARATOR
Intervention: Group DS (ONS postoperatively up to discharge)
Number of subjects: 91
Study 32687174 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphthoquine-Azithromycin (NQAZ)
Number of subjects: 631
Study 32687174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 631
Study 33676783 — intervention group
Group type: EXPERIMENTAL
Intervention: 9vHPV vaccine (three-dose regimen: day 1, month 2, month 6)
Number of subjects: 1212
Study 32914890 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 SNPs from three different loci (8p11.22, 8p12, 3q25.31)
Number of subjects: 4531
Study 32914890 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 SNPs from 3q25.31 locus
Number of subjects: 4531
Study 34791836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 88
Study 32954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive movements
Number of subjects: 39
Study 32954673 — intervention group
Group type: COMPARATOR
Intervention: Biological movements
Number of subjects: 39
Study 32954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual preference patterns
Number of subjects: 39
Study 32954673 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneity of visual preferences
Number of subjects: 39
Study 34617663 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice
Number of subjects: 38
Study 34617663 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice without KNO3
Number of subjects: 38
Study 32921364 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil containing lipid emulsion (Lipidem® 20%, BBraun) for 7 days
Number of subjects: 45
Study 32921364 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion without fish oil (Lipofundin® MCT 20%, BBraun)
Number of subjects: 45
Study 36286605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 885
Study 36286605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg
Number of subjects: 885
Study 36286605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 885
Study 34134711 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum urate (100 µmol/L)
Number of subjects: 359192
Study 34134711 — intervention group
Group type: EXPERIMENTAL
Intervention: Median serum urate (300 µmol/L)
Number of subjects: 359192
Study 32073940 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk pragmatic randomized controlled trials (pRCTs)
Number of subjects: 0
Study 32073940 — intervention group
Group type: COMPARATOR
Intervention: EU clinical trial regulation
Number of subjects: 0
Study 34923848 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous tafamidis (meglumine 80 mg)
Number of subjects: 353
Study 34923848 — intervention group
Group type: COMPARATOR
Intervention: Placebo to tafamidis
Number of subjects: 353
Study 33568796 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg daily for 12 weeks)
Number of subjects: 170
Study 33568796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 33568796 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 170
Study 32353974 — intervention group
Group type: EXPERIMENTAL
Intervention: Gymnema sylvestre (GS) solution
Number of subjects: 15
Study 32353974 — intervention group
Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 15
Study 36039531 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (two resistance sessions and one endurance session per week for 8 weeks)
Number of subjects: 40
Study 33611742 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50 mg/kg intravenously, followed by infusion at a rate of 10 mg/kg/h during surgery
Number of subjects: 52
Study 33611742 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 52
Study 35379403 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile tele-counseling
Number of subjects: 162
Study 35379403 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 162
Study 33162191 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program topics as identified by patients
Number of subjects: 38
Study 33162191 — intervention group
Group type: COMPARATOR
Intervention: Patient education program topics as identified by caregivers
Number of subjects: 38
Study 33162191 — intervention group
Group type: EXPERIMENTAL
Intervention: Common topics identified by both patients and caregivers
Number of subjects: 38
Study 35467968 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D simulator
Number of subjects: 32
Study 35467968 — intervention group
Group type: COMPARATOR
Intervention: 2D simulator
Number of subjects: 32
Study 32096321 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a history of any respiratory disease or those living in rural/remote communities
Number of subjects: 1278
Study 32096321 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 1278
Study 32096321 — intervention group
Group type: COMPARATOR
Intervention: ‘Healthy’ group
Number of subjects: 1278
Study 32096321 — intervention group
Group type: EXPERIMENTAL
Intervention: ‘Respiratory history’ group
Number of subjects: 1278
Study 34035112 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO
Number of subjects: 28
Study 34035112 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO + imiquimod
Number of subjects: 28
Study 34035112 — intervention group
Group type: COMPARATOR
Intervention: IFA
Number of subjects: 28
Study 34035112 — intervention group
Group type: COMPARATOR
Intervention: IFA + imiquimod
Number of subjects: 28
Study 34035112 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 28
Study 34035112 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (DMSO + imiquimod)
Number of subjects: 28
Study 34988991 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Formation (FF)
Number of subjects: 692
Study 34988991 — intervention group
Group type: COMPARATOR
Intervention: Economic Stability (ES)
Number of subjects: 692
Study 33743112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 493
Study 33743112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 32546148 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive case management
Number of subjects: 914
Study 32546148 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 914
Study 34788466 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 4752
Study 34788466 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 4752
Study 32871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol treatment (0.532 mg on admission, 0.266 mg on days 3 and 7, then weekly until discharge or ICU admission)
Number of subjects: 76
Study 32871238 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (hydroxychloroquine and azithromycin) without calcifediol
Number of subjects: 76
Study 32871238 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol treatment
Number of subjects: 76
Study 32871238 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy without calcifediol
Number of subjects: 76
Study 35854329 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture
Number of subjects: 198
Study 35854329 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture (non-penetrating)
Number of subjects: 198
Study 34211099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose BTxA (8 U)
Number of subjects: 22
Study 34211099 — intervention group
Group type: COMPARATOR
Intervention: Low-dose BTxA (4 U)
Number of subjects: 22
Study 32880343 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ 40 mg/kg
Number of subjects: 79
Study 32880343 — intervention group
Group type: EXPERIMENTAL
Intervention: PZQ 60 mg/kg
Number of subjects: 79
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for severe weather
Number of subjects: 614
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for act of violence
Number of subjects: 614
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for breakdown of emergency number
Number of subjects: 614
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for discovery of a World War II bomb
Number of subjects: 614
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for major fire
Number of subjects: 614
Study 33190274 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message
Number of subjects: 614
Study 32171600 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin A (BTX‐A) in the masticator muscles before surgery
Number of subjects: 20
Study 32171600 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (Control)
Number of subjects: 20
Study 33720882 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT alone (group-based CCT 3x/week for 1 hour plus 3x/week home-based training)
Number of subjects: 124
Study 33720882 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT with brisk walking (Ex+CCT)
Number of subjects: 124
Study 33720882 — intervention group
Group type: COMPARATOR
Intervention: Control group (group‐based balanced and toned (BAT) classes 3x/week for 1 hour)
Number of subjects: 124
Study 32783644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg (SPARTAN only)
Number of subjects: 0
Study 32783644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 0
Study 32783644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 0
Study 32783644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34569413 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant gel (5 ml of water-soluble lubricant gel during cervical dilatation of 4 cm until complete cervical dilatation)
Number of subjects: 110
Study 34569413 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 110
Study 32072592 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (specific intervention not detailed)
Number of subjects: 0
Study 32072592 — intervention group
Group type: COMPARATOR
Intervention: Augmented control group (external data used)
Number of subjects: 0
Study 32072592 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 0
Study 35986409 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose intake
Number of subjects: 108
Study 35986409 — intervention group
Group type: COMPARATOR
Intervention: Placebo intake
Number of subjects: 108
Study 33782121 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic supervision intervention with probation or parole officers (PPOs)
Number of subjects: 20478
Study 32473640 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-CA 2 g
Number of subjects: 15
Study 32473640 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-CA 4 g
Number of subjects: 15
Study 32473640 — intervention group
Group type: EXPERIMENTAL
Intervention: OM3-EE 4 g
Number of subjects: 15
Study 33183170 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the theory of planned behavior
Number of subjects: 140
Study 33183170 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-training)
Number of subjects: 140
Study 32281915 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (1.5g per day for 2 weeks)
Number of subjects: 20
Study 32281915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 36371148 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP10
Number of subjects: 120
Study 36371148 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP5
Number of subjects: 120
Study 36371148 — intervention group
Group type: COMPARATOR
Intervention: PEEP0
Number of subjects: 120
Study 33002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 3 mg/kg
Number of subjects: 175
Study 33002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 6 mg/kg
Number of subjects: 175
Study 33002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ALX‐0171 9 mg/kg
Number of subjects: 175
Study 33002427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 33002427 — intervention group
Group type: EXPERIMENTAL
Intervention: All ALX‐0171 groups
Number of subjects: 175
Study 36260394 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention with a 4-hour tailored lifestyle education session and personalized goal setting
Number of subjects: 123
Study 36260394 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth behavior change intervention
Number of subjects: 123
Study 36260394 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 123
Study 32221987 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam at individualized doses ≤200 mg/d
Number of subjects: 667
Study 36432445 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated beetroot juice (140 mL)
Number of subjects: 18
Study 36432445 — intervention group
Group type: COMPARATOR
Intervention: Low-nitrate control supplement
Number of subjects: 18
Study 34768404 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin (1.5 g/kg at baseline and 1 g/kg on day 3)
Number of subjects: 82
Study 34768404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34768404 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 82
Study 35303460 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based programme for corneal ulcer prevention involving training of female community health volunteers (FCHVs) to diagnose corneal abrasions and provide a 3-day course of ophthalmic antimicrobials.
Number of subjects: 252539
Study 35303460 — intervention group
Group type: COMPARATOR
Intervention: Control group with no intervention provided by FCHVs.
Number of subjects: 252539
Study 33152277 — intervention group
Group type: EXPERIMENTAL
Intervention: IM‐MS irradiation at 50 Gy in 25 fractions
Number of subjects: 4004
Study 33152277 — intervention group
Group type: COMPARATOR
Intervention: No IM‐MS irradiation (control group)
Number of subjects: 4004
Study 36041466 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of stuttering
Number of subjects: 238
Study 36041466 — intervention group
Group type: EXPERIMENTAL
Intervention: Low communication competence with disclosure
Number of subjects: 238
Study 36041466 — intervention group
Group type: EXPERIMENTAL
Intervention: High communication competence
Number of subjects: 238
Study 36041466 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of self-disclosure and high communication competence
Number of subjects: 238
Study 33306991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg ID93 + 5 μg GLA‐SE on days 0 and 56
Number of subjects: 61
Study 33306991 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg ID93 + 5 μg GLA‐SE on days 0, 28, and 56
Number of subjects: 61
Study 33306991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 35648041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone (Ld arm)
Number of subjects: 65
Study 35648041 — intervention group
Group type: COMPARATOR
Intervention: Autologous stem cell transplantation (ASCT) (Ld + ASCT arm)
Number of subjects: 65
Study 33413345 — intervention group
Group type: EXPERIMENTAL
Intervention: Apabetalone
Number of subjects: 2425
Study 32068895 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress tolerance in schizophrenia
Number of subjects: 87
Study 32068895 — intervention group
Group type: COMPARATOR
Intervention: Distress tolerance in borderline personality disorder (BPD)
Number of subjects: 87
Study 35114131 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu‐Dotatate plus long‐acting octreotide
Number of subjects: 117
Study 35114131 — intervention group
Group type: COMPARATOR
Intervention: High‐dose long‐acting octreotide
Number of subjects: 117
Study 34347216 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + IVR
Number of subjects: 28
Study 34347216 — intervention group
Group type: EXPERIMENTAL
Intervention: PIR + IVR
Number of subjects: 28
Study 35222756 — intervention group
Group type: EXPERIMENTAL
Intervention: IntellaTip MiFi catheter using ME signals alone
Number of subjects: 61
Study 35222756 — intervention group
Group type: COMPARATOR
Intervention: Standard 8 mm non-irrigated catheter with bipolar signals
Number of subjects: 61
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 549
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus complex fractionated electrograms
Number of subjects: 549
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI plus linear lesions
Number of subjects: 549
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: No recurrence of AF
Number of subjects: 549
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of AF
Number of subjects: 549
Study 33275151 — intervention group
Group type: EXPERIMENTAL
Intervention: AF burden reduction
Number of subjects: 549
Study 35680270 — intervention group
Group type: EXPERIMENTAL
Intervention: Community organisation targeted multicomponent education and training initiative on CPR and OHCA over 12 months
Number of subjects: 200
Study 35680270 — intervention group
Group type: COMPARATOR
Intervention: Delayed programme implementation (Control)
Number of subjects: 200
Study 34004400 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical Resources for Effective Postpartum Parenting (PREPP)
Number of subjects: 109
Study 34004400 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 109
Study 32891560 — intervention group
Group type: EXPERIMENTAL
Intervention: Labia minora and clitoral hood creation (group A)
Number of subjects: 167
Study 32891560 — intervention group
Group type: COMPARATOR
Intervention: No labia minora and clitoral hood creation (group B)
Number of subjects: 167
Study 34636086 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit (12 weeks of tailored, smoking cessation text messages)
Number of subjects: 1002
Study 34636086 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1002
Study 34636086 — intervention group
Group type: EXPERIMENTAL
Intervention: MiQuit
Number of subjects: 1002
Study 34636086 — intervention group
Group type: COMPARATOR
Intervention: MiQuit and UC (TSA meta-analysis)
Number of subjects: 1002
Study 33831909 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to a single-tablet regimen of cobicistat, elvitregravir, emtricitabine along with tenofovir alafenamide
Number of subjects: 50
Study 33831909 — intervention group
Group type: COMPARATOR
Intervention: Two-drug regimen based on dolutegravir and one reverse transcriptase inhibitor (RTI)
Number of subjects: 50
Study 36687270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 55
Study 36687270 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 55
Study 36687270 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 55
Study 33428320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physiotherapy (PFP), 5 individual sessions
Number of subjects: 34
Study 33428320 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor physiotherapy (PFP)
Number of subjects: 34
Study 33428320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 33951066 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants from African regions
Number of subjects: 289
Study 33951066 — intervention group
Group type: COMPARATOR
Intervention: Participants from non-African regions
Number of subjects: 289
Study 33378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT) at a cutoff value of 20 μg Hb/g
Number of subjects: 3407
Study 33378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT) at a decreased cutoff value of 5 μg Hb/g
Number of subjects: 3407
Study 33378824 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative fecal immunochemical test (FIT)
Number of subjects: 3407
Study 36477547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass azithromycin distributions
Number of subjects: 60
Study 36477547 — intervention group
Group type: COMPARATOR
Intervention: No treatments (control group)
Number of subjects: 60